Equillium SEC Filings

Equillium, Inc. filed a Form 8-K reporting a letter from independent auditor KPMG LLP dated October 6, 2025. The company states that KPMG reported no disagreements with management on accounting principles, financial statement disclosure, or audit scope, and identified no reportable events as defined under Regulation S‑K. A copy of KPMG's letter is attached as Exhibit 16.1. The filing also notes the Cover Page Interactive Data File is embedded with the Inline XBRL document. The report is signed by Bruce D. Steel, Chief Executive Officer.

Equillium, Inc. reports an estimated public float of $93.7 million, calculated from 47,085,662 shares held by non-affiliates and a per‑share price of $1.99. The $1.99 price was the highest closing price on The Nasdaq Capital Market within 60 days of this prospectus supplement's filing, specifically on September 11, 2025. The public float figure follows the method in General Instruction I.B.6 of Form S-3 under the Securities Act of 1933.

The company notes this figure is specific to the current filing and that if it later becomes subject to the limitations in General Instruction I.B.6, it will file another supplement to update the ATM prospectus. No other financial results, transactions, or forward-looking statements are provided in this excerpt.

Equillium, Inc. filed an S-3 shelf registration to register common stock for resale by selling stockholders, including shares issuable upon exercise of pre-funded warrants sold in a recent private placement. The prospectus identifies multiple institutional holders (including Adage, ADAR1 Entities, Coastlands Capital and Janus) and shows specific share counts and warrants subject to beneficial ownership blockers that exclude certain exercisable shares from pre-offering ownership figures. The filing lists exhibits (e.g., merger agreement, charter documents, Registration Rights Agreement dated August 12, 2025 and pre-funded warrant form dated August 11, 2025) and incorporates prior SEC reports by reference. The total filing fee shown aggregates to $81,562.

Equillium, Inc. (EQ) reporting person Stephen Connelly, Chief Scientific Officer and Director, received an employee stock option award covering 1,025,000 shares on 08/29/2025 with an exercise price of $1.74. The filing shows the option as acquired (code A) and lists 1,025,000 shares beneficially owned following the transaction. The explanatory note states standard time-based vesting: 25% vest on the first anniversary of the vesting commencement date and the remainder vests in 36 equal monthly installments thereafter.

Tom Penny, Principal Accounting Officer and director at Equillium, Inc. (EQ), was granted an employee stock option on 08/29/2025. The option permits purchase of 525,000 shares of common stock at an exercise price of $1.74 per share and expires on 08/28/2035. Under the stated vesting schedule, 25% of the option vests on the first anniversary of the vesting commencement date and the remainder vests monthly over the following three years. The shares reported as beneficially owned following the grant are 525,000, held directly by the reporting person.

Equillium, Inc. (EQ) insider filing reports an equity award granted to Christine Zedelmayer, Sr. Vice President and COO. The Form 4 shows an employee stock option transaction dated 08/29/2025 for 725,000 options with an exercise price of $1.74. Following the grant, the filing reports 725,000 shares underlying the option as beneficially owned by the reporting person.

The filing includes a vesting schedule: 25% of the option shares vest on the first anniversary of the vesting commencement date, with the remainder vesting in 36 equal monthly installments thereafter. The option entry lists an associated date of 08/28/2035 in the table for exercisability/expiration fields as provided in the filing.